For more than four decades, Fenwick & West LLP has helped some of the world’s most recognized companies become, and remain, market leaders. From emerging enterprises to large public corporations, our clients are leaders in the technology, life sciences and cleantech sectors and are fundamentally changing the world through rapid innovation.  MORE >

Fenwick & West was founded in 1972 in the heart of Silicon Valley—before “Silicon Valley” existed—by four visionary lawyers who left a top-tier New York law firm to pursue their shared belief that technology would revolutionize the business world and to pioneer the legal work for those technological innovations. In order to be most effective, they decided they needed to move to a location close to primary research and technology development. These four attorneys opened their first office in downtown Palo Alto, and Fenwick became one of the first technology law firms in the world.  MORE >

From our founding in 1972, Fenwick has been committed to promoting diversity and inclusion both within our firm and throughout the legal profession. For almost four decades, the firm has actively promoted an open and inclusive work environment and committed significant resources towards improving our diversity efforts at every level.  MORE >

At Fenwick, we are proud of our commitment to the community and to our culture of making a difference in the lives of individuals and organizations in the communities where we live and work. We recognize that providing legal services is not only an essential part of our professional responsibility, but also an excellent opportunity for our attorneys to gain valuable practical experience, learn new areas of the law and contribute to the community.  MORE >

Year after year, Fenwick & West is honored for excellence in the legal profession. Many of our attorneys are recognized as leaders in their respective fields, and our Corporate, Tax, Litigation and Intellectual Property Practice Groups consistently receive top national and international rankings, including:

  • Nearly 15 percent of Fenwick partners named America's Leading Lawyers for Business by Chambers USA and Chambers Global
  • Selected as a "Go-To" law firm by in-house legal departments at Fortune 500 companies in Corporate Counsel magazine
  • Named to The National Law Journal's inaugural "Intellectual Property Hot List" for outstanding patent, copyright, trademark and IP litigation services


We take sustainability very seriously at Fenwick. Like many of our clients, we are adopting policies that reduce consumption and waste, and improve efficiency. By using technologies developed by a number of our cleantech clients, we are at the forefront of implementing sustainable policies and practices that minimize environmental impact. In fact, Fenwick has earned recognition in several areas as one of the top US law firms for implementing sustainable business practices.  MORE >

At Fenwick, we have a passion for excellence and innovation that mirrors our client base. Our firm is making revolutionary changes to the practice of law through substantial investments in proprietary technology tools and processes—allowing us to deliver best-in-class legal services more effectively.   MORE >

Mountain View Office
Silicon Valley Center
801 California Street
Mountain View, CA 94041

San Francisco Office
555 California Street
12th Floor
San Francisco, CA 94104

Seattle Office
1191 Second Avenue
10th Floor
Seattle, WA 98101

Shanghai Office
36/F, Room 3690, Tower 2
Shanghai IFC
8 Century Avenue, Pudong
Shanghai 200120, China
+86 21 6062 6104

Andrew T. Serafini, Ph.D.

Partner, Intellectual Property

icon partner 206.389.4596  

Office: Seattle

Andrew Serafini focuses his practice on strategic and comprehensive intellectual property counseling and management to biotechnology, biopharmaceutical and other life sciences clients. His efforts help them obtain, protect and enforce their intellectual property rights, especially in the areas of immunology, molecular biology, antibody engineering and therapeutics, vaccines, stem cell technologies, molecular genetics, genomics, proteomics and protein chemistry, pharmaceuticals, medical therapeutics, nanotechnology, cleantech, medical diagnostics and personalized medicine.

Andrew’s practice involves preparing and prosecuting U.S. and international patents; performing due diligence and freedom to operate analyses associated with mergers and acquisitions, venture capital and other private and public financings; drafting opinions on patentability, non-infringement and patent validity; product development counseling; oppositions and arbitrations; and supporting technology litigation.

Andrew works closely with the venture capital community to help build life sciences start-up companies into industry market leaders. He also partners with public and private universities and research institutions to help safeguard, leverage and bring to market their technology assets and innovations as well as facilitate the technology transfer of these assets and innovations to foster further developments to benefit the public.

Andrew is an Adjunct Professor of Law at the University of Washington School of Law where he teaches advanced courses in intellectual property with a focus on patent law. He also advises and mentors University of Washington School of Law students participating in independent study programs and law clinics, including the University of Washington School of Law Entrepreneurial Law Clinic.

Andrew is a member of the Seattle Trade Development Alliance Advisory Council as well as the China Policy Committee for the Washington Council on International Trade. He is also on the board of directors for the Washington Rush premier youth soccer club. Prior to joining Fenwick & West, he was a partner in the Seattle office of Woodcock Washburn LLP.

Andrew was recognized as the Volunteer of the Year by the Washington Biotechnology & Biomedical Association (WBBA) at the 2013 Governor’s Life Science Summit and WBBA Annual Meeting.

Andrew was also recognized as a "Rising Star" in the area of Intellectual Property by Washington SuperLawyers in 2011 and 2013. In 2014, Intellectual Asset Management magazine named Andrew to the IAM Patent 1000: The World’s Leading Patent Practitioners.

Professional and life sciences industry organizations

  • American Bar Association
  • Washington State Bar Association
  • American Intellectual Property Association
  • Washington State Patent Law Association
  • Silicon Valley Intellectual Property Law Association
  • Licensing Executive Society (U.S.A. & Canada) Inc.
  • Association of University Technology Managers
  • Biotechnology Industry Organization
  • Washington Biotechnology and Biomedical Association
  • American Association of the Advancement of Science


  • Gene Patents, Diagnostics, Precision Medicine, and Human Therapeutic Antibodies: After Myriad, Human Antibody & Hybridoma 2014 Conference, Vienna, Austria, March 31, 2014.
  • Public Health & Genetics - The Myriad Impact on Precision Medicine, University of Washington Public Health Genetics Class, Seattle, Washington, January 27, 2014.
  • Gene Patents, Diagnostics, and Precision Medicine: After Prometheus and Myriad, The Seattle Forum on Science Ethics and Policy (FOSEP), Seattle, Washington, December 11, 2013.
  • Gene Patents, Diagnostics, and Precision Medicine:  After Prometheus and Myriad, University of Washington School of Law, The Center for Advanced Study & Research on Intellectual Property (CASRIP) Patent and Intellectual Property Law and Practice Summer Institute, Seattle, Washington, July 29, 2013.
  • Entering the Chinese Market, Society of Trust and Estate Practitioners (STEP), Seattle, Washington, May 2013.
  • Gene Patents, Diagnostics, and Precision Medicine: After Prometheus and Myriad, University of Washington School of Law, Genetics and The Law, Seattle, Washington, May 2013.
  • Seeds of Exhaustion: Analysis of Bowman v. Monsanto and the Shifting Doctrine of Patent Exhaustion, BIO Intellectual Property Counsels Conference & Meeting, San Diego, California, March 2013.
  • Introduction to Design Patents, University of Washington School of Law, Entrepreneurial Law Clinic, Seattle, Washington, February 2013.
  • The Experimental Use Exception & Patent Exhaustion: Patent Issues From A Global Perspective, University of Washington School of Law, Advanced Patent Law, Seattle, WA, January 2013.
  • 2012 U.S. Biotech Patent Law Jurisprudence, The Chartered Institute of Patent Attorneys Life Sciences 2012 Conference, Bedfordshire, England, United Kingdom, November 2012.
  • Monoclonal Antibody Patents: Evolving law & strategies, Human Antibody & Hybridoma Conference, Orlando, Florida, November 2012.
  • Business Partnerships and Investment: Intellectual Property Licensing Due Diligence, Korean International Trade Association (KITA) Conference/Washington State Trade Mission to Korea, Seoul, Korea, October 2012.
  • Patent Eligibility, Written Description and Inequitable Conduct, University of Washington School of Law, The Center for Advanced Study & Research on Intellectual Property (CASRIP) Patent and Intellectual Property Law and Practice Summer Institute, Seattle, WA, July 2012.
  • Classen, Prometheus, & Myriad: 35 U.S.C. 101 – Patent Eligibility, IP Protection in the Information Age, Law School and Intellectual Property Academy, Renmin University of China, Beijing, China, June 2012.
  • Harnessing Innovation for Global Development, Tokyo Medical and Dental University/Waseda Law School Global Health Conference, Tokyo, Japan, June 2012.
  • Challenges in Starting Diagnostic and Medical Device Companies, InnovFest 2012-AUTM Asia/Technology Commercialisation Forum, Singapore, April 2012.
  • Intellectual Property: What It Is, What It Isn’t, How To Protect It and How To Avoid It, University of Washington Entrepreneurial Law Clinic, Seattle, Washington, November 2011.
  • Centocor vs. Abbott: Are US Courts Losing Their Affinity for Broad Antibody Patent Protection?, Human Antibody & Hybridoma 2011 Conference, Cannes, France, November 2011.
  • WBBA Stem Cell & Regenerative Medicine: Today and Tomorrow, Recipe for Success, University of Washington Institute for Stem Cell and Regenerative Medicine, Seattle, Washington, September 2011.
  • Impact of Patent Policy on Personalized Medicine, Investment & Innovation, University of Washington School of Law, The Center for Advanced Study & Research on Intellectual Property (CASRIP) Patent and Intellectual Property Law and Practice Summer Institute, Seattle, WA, July 2011.
  • Technology Transfer Practice Today: Scope of Upstream Inventions, Tokyo Medical and Dental University, Tokyo, Japan, June 2011.
  • Genomic Biology: Patentability, Trends and Freedom to Operate, PROOF Centre of Excellence, Vancouver, British Columbia, May 2011.
  • A Landmark Case: The Aftermath of Myriad, BIO Intellectual Property Counsels Committee Conference, Seattle, Washington, April 2011.
  • Therapeutics and Antibodies, National University of Singapore, Technology Commercialisation Forum, Singapore, April 2011.
  • Current Issues in Biotechnology Patenting in China and the United States, PTO/SIPO/Industry Biotech Patenting Workshop, Beijing, China, March 2011.
  • Making It Personal-Challenges and Strategies for Patenting Genetic Technologies, Best Practices for Personalized Medicine (B2PM) Conference, Vancouver, British Columbia, March 2011.
  • Intellectual Property Due Diligence/Freedom-To-Operate Strategies for Emerging Companies, University of Washington Entrepreneurial Law Clinic, Seattle, WA, February 2011.
  • Future of a Field: Stem Cells, AUTM 2010 Western Region Meeting, Los Angeles, CA, October 2010.
  • Biotech/Pharmaceutical Dispute Resolution, University of Washington School of Law, The Center for Advanced Study & Research on Intellectual Property (CASRIP) Patent and Intellectual Property Law and Practice Summer Institute, Seattle, WA, July 2010.
  • Patent Prosecution Fundamentals and Strategic Patent Portfolio Development, Puget Sound Blood Center, June and July 2010.
  • The impact of Ariad Pharmaceuticals, Inc. v. Eli Lily & Company and In re Bilski on Life Science Patent Portfolio Strategies, Tokyo Medical Dental University, Tokyo, Japan & Osaka Institute of Technology, Osaka, Japan, June 2010.
  • Hot Topics in Patent Law and Licensing for Universities, University of Washington Center for Commercialization, Seattle, WA, May 2010.
  • The Business of Antibodies - How to Protect and Commercialize Antibodies, Human Antibody & Hybridoma Meeting, Porto, Portugal, April 2010.
  • Regenerative Medicine Technologies: Patenting, Licensing, and Commercializing Strategies, International Industry-University Collaboration Symposium, Keio University Symposium, Tokyo, Japan, March 2010.
  • Bringing Early Stage Technologies to Market, Technology Commercialization Forum, Singapore, March 2010.
  • Current Issues in Pharmaceutical Patents, University of Washington School of Law, Seattle, Washington, March 2010.



About Andrew